SQLite Web: event_store.db

Update row 39633 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-14T02:04:49.876253+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:14c5c24fb51ea252","evidence_event_ids":["evt_69577143f785"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-024940.txt","as_of":"2026-04-14T02:04:49.876253+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-024940.txt","company":"Spyre Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-024940.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_7a58afaaaeaaed45","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-024940.txt","content_type":"text/plain","enriched_at":"2026-04-14T02:25:54.730337+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"Document","final_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-024940.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-024940.txt","source_event_id":"evt_69577143f785","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"424B5","fp":"65cfa7905dced283","kind":"sec_filing","published_at":"20260413","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-13","2026-04-10","2026-02-27","2026-02-19","2026-02-27"],"entities":[{"asset_class":"equity","name":"Spyre Therapeutics, Inc.","relevance":"primary","symbol":"SYRE","type":"issuer"},{"asset_class":"market","name":"Nasdaq Global Select Market","relevance":"secondary","symbol":"","type":"exchange"},{"asset_class":"equity_underwriting","name":"LifeSci Capital","relevance":"secondary","symbol":"","type":"underwriter"}],"event_type":"listing","information_gaps":["The public offering price per share is not shown in the provided text (appears as a blank).","The number of additional shares subject to the underwriters\u2019 option is not provided (blank in text).","The expected delivery date is not provided (blank in text).","No explicit comparison to a prior known state is included in the provided text beyond the fact that this is a preliminary prospectus supplement; the prior filing details are not provided here."],"key_facts":["Form type: 424B5.","Filed pursuant to Rule 424(b)(5) under Registration Statement No. 333-293600.","Prospectus supplement is dated April 13, 2026 and relates to a prospectus dated February 27, 2026.","Issuer offers $300,000,000 of common stock (par value $0.0001 per share).","Issuer\u2019s common stock trades on Nasdaq Global Select Market under symbol \u201cSYRE.\u201d","Last reported sale price per share on April 10, 2026 was $51.29.","Underwriters have an option to purchase up to an additional shares of common stock within 30 days of the date of the prospectus supplement (amount not filled in the provided text).","The document states it is a preliminary prospectus supplement subject to completion and may be changed.","The underwriters expect to deliver the shares on or about [date not provided in text], 2026."],"numeric_claims":[{"label":"offering_size_usd","value":"$300,000,000"},{"label":"par_value_usd_per_share","value":"$0.0001"},{"label":"last_reported_sale_price_per_share_usd","value":"$51.29"}],"primary_claim":"SYRE (Spyre Therapeutics, Inc.) filed a Form 424B5 preliminary prospectus supplement to offer $300,000,000 of its common stock under a shelf registration.","relevance_score":0.72,"sentiment":"neutral","source_quality":"high","summary":"Spyre Therapeutics, Inc. filed a preliminary prospectus supplement on Form 424B5 under its effective shelf registration to offer $300,000,000 of common stock. The filing includes offering mechanics (including an underwriters\u2019 option) and references a last reported Nasdaq price of $51.29 on April 10, 2026.","topics":["SEC filing","prospectus supplement","common stock offering","shelf registration","underwriting"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 424B5 \u00b7 Spyre Therapeutics, Inc. \u00b7 Filed 20260413","ticker":"SYRE","tickers":["SYRE"],"title":"SYRE filed 424B5","url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-024940.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel